Form name
Number of respondents HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions, (2) the accuracy of the estimated burden, (3) ways to enhance the quality, utility, and clarity of the information to be collected, and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden. During the meeting, the Working Group will review and discuss the content of the five draft chapters that will be part of the Report to Congress. Persons who wish to receive the draft document should email the tickbornedisease@hhs.gov and request a copy. The document will be available prior to the meeting.
Background and Authority: The TickBorne Disease Working Group was established on August 10, 2017, in accordance with section 2062 of the 21st Century Cures Act, and the Federal Advisory Committee Act, 5 U.S.C. App., as amended, to provide expertise and review all HHS, DoD and VA efforts related to tick-borne diseases to help ensure interagency coordination and minimize overlap, examine research priorities, and identify and address unmet needs. In addition, the Working Group is required to submit a report to the Secretary and Congress on their findings and any recommendations for improving the federal response to tickborne disease prevention, treatment and research, and addressing gaps in those areas. Specifically, Respondent knowingly and intentionally falsified and/or fabricated:
• Unique sequences and stability data for 1017 active Rop variants in Table  3 .1 and provided additional analyses purportedly from those active Rop variants in Table 3.2 and Figures 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, and 3.9 in his thesis and in Figures 6, 7 , 17, and 20 in two (2) grant applications • unique sequences and stability data for active Rop loop variants from four separate mutant libraries, X 4 , LX 4 , X 4 -I, LX 4 -I in Tables 5.2 Tables 9.2, 9 .3, and 9.4 in his thesis ORI also found that Respondent knowingly and intentionally falsified and/or fabricated HTTS data for thermodynamic effects of somatic mutation in antibodies 93F3 and OKT3 in ten (10) (1) To exclude himself voluntarily from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement programs of the United States Government referred to as ''covered transactions'' pursuant to HHS' Implementation (2 CFR part 376) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ''Debarment Regulations'');
(2) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
